Cytomegalovirus infection in pediatric immunocompromised hosts

Infectious Disorders - Drug Targets

Volumn 11, Issue 5, 2011, Pages 437-448

  Russell, Marsha Y ^a   Palmer, April ^b   Michaels, Marian G ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Immunocompromised hosts; Immunosuppressed; Infections; Opportunistic; Prematurity; Transplant

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AZATHIOPRINE; CIDOFOVIR; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; VALGANCICLOVIR;

ARTICLE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EPIDEMIC; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY DYSFUNCTION; LATENT VIRUS INFECTION; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PREMATURITY; RISK FACTOR; VEIN OCCLUSION; VIRUS REACTIVATION; VIRUS STRAIN;

EID: 80054104784     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611797636686     Document Type: Article

References (105)

1. Humar, A.; Snydman, D.; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant., 2009, 9 (Suppl. 4), S78-S86.
2. Ho, M. Cytomegalovirus: Biology and Infection, Plenum Publishing Corporation: New York, 1991.
3. Elliott, S.P. Congenital cytomegalovirus infection: an overview. Infect. Disord. Drug Targets, 2011, 11, 432-436.
4. Mañez, R.; St George, K.; Linden P.; Martin, M.; Kusne, S.; Grossi, P.; Ho, M.; Rinaldo, C. Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis. J. Clin. Microbiol., 1994, 32 (11), 2655-2659.
5. Humar, A.; Michaels, M.; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant., 2006, 6 (2), 263-274.
6. Ljungman, P.; Griffiths, P.; Paya, C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis., 2002, 34 (8), 1094-1097.
7. St George, K.; Boyd, M.J.; Lipson, S.M.; Ferguson, D.; Cartmell, G.F.; Falk, L.H.; Rinaldo, C.R.; Landry, M.L. A multisite trial comparing two cytomegalovirus (CMV) pp65 antigenemia test kits, biotest CMV brite and Bartels/Argene CMV antigenemia. J. Clin. Microbiol., 2000, 38 (4), 1430-1433.
8. Pang, X.L.; Fox, J.D.; Fenton, J.M.; Miller, G.G.; Caliendo, A.M.; Preiksaitis, J.K.; American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant., 2009, 9 (2), 258-268.
9. Hobbs, J.R.; Davis, J.A. Serum gamma-G-globulin levels and gestational age in premature babies. Lancet, 1967, 1 (7493), 757-759.
10. Lawrence, R.M. Cytomegalovirus in human breast milk: risk to the premature infant. Breastfeed. Med., 2006, 1 (2), 99-107.
11. Elbou Ould, M.A.; Luton, D.; Yadini, M.; Pedron, B.; Aujard, Y.; Jacqz-Aigrain, E.; Jacquemard, F.; Sterkers, G. Cellular immune response of fetuses to cytomegalovirus. Pediatr. Res., 2004, 55 (2), 280-286.
12. Capretti, M.G.; Lanari, M.; Lazzarotto, T.; Gabrielli, L.; Pignatelli, S.; Corvaglia, L.; Tridapalli, E.; Faldella, G. Very low birth weight infants born to cytomegalovirus-seropositive mothers fed with their mother's milk: a prospective study. J. Pediatr., 2009, 154 (6), 842-848.
13. Hamprecht, K.; Maschmann, J.; Vochem, M.; Dietz, K.; Speer, C.P.; Jahn, G. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet, 2001, 357 (9255), 513-518.
14. Hamprecht, K.; Maschmann, J.; Jahn, G.; Poets, C.F.; Goelz, R. Cytomegalovirus transmission to preterm infants during lactation. J. Clin. Virol., 2008, 41 (3), 198-205.
15. Maschmann, J.; Hamprecht, K.; Dietz, K.; Jahn, G.; Speer, C.P. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin. Infect. Dis., 2001, 33 (12), 1998-2003.
16. Gessler, P.; Bischoff, G.A.; Wiegand, D.; Essers, B.; Bossart, W. Cytomegalovirus -associated necrotizing enterocolitis in a preterm twin after breastfeeding. J. Perinatol., 2004, 24 (2), 124-126.
17. Demmler, G.J.; Brady, M.T.; Bijou, H.; Speer, M.E.; Milam, J.D.; Hawkins, E.P.; Anderson, D.C.; Six, H.; Yow, M.D. Posttransfusion cytomegalovirus infection in neonates: role of saline-washed red blood cells. J. Pediatr., 1986, 108 (5 pt. 1), 762-765.
18. Preiksaitis, J.K. The cytomegalovirus-safe blood product: is leukoreduction equivalent to antibody screening? Transfus. Med. Rev., 2000, 14 (2), 112-136.
19. Curtis, N.; Chau, L.; Garland, S.; Tabrizi, S.; Alexander, R.; Morley, C.J. Cytomegalovirus remains viable in naturally infected breast milk despite being frozen for 10 days. Arch. Dis. Child. Fetal Neonatal Ed., 2005, 90 (6), F529-F530.
20. Lee, H.C.; Enright, A.; Benitz, W.E.; Madan, A. Postnatal cytomegalovirus infection from frozen breast milk in preterm, low birth weight infants. Pediatr. Infect. Dis. J., 2007, 26 (3), 276.
21. Goelz, R.; Hihn, E.; Hamprecht, K.; Dietz, K.; Jahn, G.; Poets, C.; Elmlinger, M. Effects of different CMV-heat-inactivation methods on growth factors in human breast milk. Pediatr. Res., 2009, 65 (4), 458-461.
22. Radi, S.; Janvresse, C.; Lardennois, C.; Michel, C.; Brossard, V.; Marret, S. Breastfeeding and cytomegalovirus infection in preterm infants. How to reduce the risks? Arch. Pediatr. Arch. Pediatr., 2007, 14 (1), 31-35.
23. ® 64th edition Physician's Desk Reference 2010, pp. 2872-2880.
24. Mosca, F.; Pugni, L.; Barbi, M.; Binda, S. Transmission of cytomegalovirus. Lancet, 2001, 357 (9270), 1800.
25. Snydman, D.R.; Werner, B.G.; Meissner, H.C.; Cheeseman, S.H.; Schwab, J; Bednarek, F.; Kennedy, J.L., Jr., Herschel, M.; Magno, A.; Levin, M.J.; Valaes, T.; Berkman, E.; McIver, J.; Leszczynski, J.; Griffith, J.; Grady, G.F. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr. Infect. Dis. J., 1995, 14 (1), 34-40.
26. Fishman, J.A. Infection in solid-organ transplant recipients. N. Engl. J. Med., 2007, 357 (25), 2601-2614.
27. Patel, R.; Paya, C.V. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev., 1997, 10 (1), 86-124.
28. Duncan, A.J.; Dummer, J.S.; Paradis, I.L.; Dauber, J.H.; Yousem, S.A.; Zenati, M.A.; Kormos, R.L.; Griffith, B.P. Cytomegalovirus infection and survival in lung transplant recipients. J. Heart Lung Transplant, 1991, 10 (5 pt. 1), 638-644.
29. Green, M.; Wald, E.R.; Fricker, F.J.; Griffith, B.P.; Trento, A. Infections in pediatric orthotopic heart transplant recipients. Pediatr. Infect. Dis. J., 1989, 8 (2), 87-93.
30. Rubin, R.H. Cytomegalovirus in solid organ transplantation. Transpl. Infect. Dis., 2001, 3 (Suppl. 2), 1-5.
31. Pescovitz, M.D. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation, 2006, 82 (2 Suppl.), S4-S8.
32. Green, M.; Michaels, M.G. In: Infections in Solid-Organ Transplant Recipients. Principles and Practice of Pediatric Infectious Diseases; Long, S.S., Pickering, L.K., Prober, C.G., Eds.; Churchill Livingstone: Philadelphia, 2009; pp. 551-562.
33. Danziger-Isakov, L.A.; DelaMorena, M.; Hayashi, R.J.; Sweet, S.; Mendeloff, E.; Schootman, M.; Huddleston, C.B.; DeBaun, M.R. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation, 2003, 75 (9), 1538-1543.
34. Sagedal, S.; Nordal, K.P.; Hartmann, A.; Sund, S.; Scott, H.; Degré, M.; Foss, A.; Leivestad, T.; Osnes, K.; Fauchald, P.; Rollag, H. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant., 2002, 2 (9), 850-856.
35. Fishman, J.A.; Emery, V.; Freeman, R.; Pascual, M.; Rostaing, L.; Schlitt, H.J.; Sgarabotto, D.; Torre-Cisneros, J.; Uknis, M.E. Cytomegalovirus in transplantation - challenging the status quo. Clin. Transplant., 2007, 21 (2), 149-158.
36. Kranz, B.; Vester, U.; Wingen, A.M.; Nadalin, S.; Paul, A.; Broelsch, C.E.; Hoyer, P.F. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr. Transplant., 2008, 12 (4), 474-478.
37. Mwintshi, K.; Brennan, D.C. Prevention and management of cytomegalovirus infection in solid-organ transplantation. Expert Rev. Anti. Infect. Ther., 2007, 5 (2), 295-304.
38. Green, M.; Michaels, M.G. Infectious complications of immunosuppressive medications in organ transplant recipients. Pediatr. Infect. Dis. J., 2007, 26 (5), 443-444.
39. Bartosh, S.M.; Ryckman, F.C.; Shaddy, R.; Michaels, M.G.; Platt, J.L.; Sweet, S.C. A national conference to determine research priorities in pediatric solid organ transplantation. Pediatr. Transplant., 2008, 12 (2), 153-166.
40. Green, M.; Michaels, M.G.; Katz, B.Z.; Burroughs, M.; Gerber, D.; Shneider, B.L.; Newell, K.; Rowe, D.; Reyes, J. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am. J. Transplant., 2006, 6 (8), 1906-1912.
41. Simmonds, J.; Fenton, M.; Dewar, C.; Ellins, E.; Storry, C.; Cubitt, D.; Deanfield, J.; Klein, N.; Halcox, J.; Burch, M. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation, 2008, 117 (20), 2657-2661
42. Danziger-Isakov, L.A.; Worley, S.; Michaels, M.G.; Arrigain, S.; Aurora, P.; Ballmann, M.; Boyer, D.; Conrad, C.; Eichler, I.; Elidemir, O.; Goldfarb, S.; Mallory, G.B.; Mogayzel, P.J.; Parakininkas, D.; Solomon, M.; Visner, G.; Sweet, S.; Faro, A. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. Transplantation, 2009, 87 (10), 1541-1548.
43. Webber, S.A. Cytomegalovirus infection and cardiac allograft vasculopathy in children. Circulation, 2007, 115 (13), 1701-1702.
44. Preiksaitis, J.K.; Brennan, D.C.; Fishman, J.; Allen, U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am. J. Transplant., 2005, 5 (2), 218-227
45. Danziger-Isakov, L.; Baillie, G.M. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin. Transplant., 2009, 23 (3), 295-304.
46. Gerna, G.; Lilleri, D.; Callegaro, A.; Goglio, A.; Cortese, S.; Stroppa, P.; Torre, G. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation, 2008, 86 (1), 163-166.
47. Spivey, J.F.; Singleton, D.; Sweet, S.; Storch, G.A.; Hayashi, R.J.; Huddleston, C.B.; Danziger-Isakov, L.A. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr. Transplant., 2007, 11 (3), 312-318.
48. Madan, R.P.; Campbell, A.L.; Shust, G.F.; Kahn, A.R.; Wistinghausen, B.; Posada, R.; Kerkar, N.; Shneider, B.L.; Emre, S.; Herold, B.C. A hybrid strategy for the prevention of cytomegalovirus- related complications in pediatric liver transplantation recipients. Transplantation, 2009, 87 (9), 1318-1324.
49. Vaudry, W.; Ettenger, R.; Jara, P.; Varela-Fascinetto, G.; Bouw, M.R.; Ives, J.; Walker, R.; Valcyte WV16726 Study Group. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am. J. Transplant., 2009, 9 (3), 636-643.
50. Paya, C.; Humar, A.; Dominguez, E.; Washburn, K.; Blumberg, E.; Alexander, B.; Freeman, R.; Heaton, N.; Pescovitz, M.D.; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant., 2004, 4 (4), 611-620.
51. Ahmed, A. Infect. Disord. Drug Targets, 2011, 11, 475-503.
52. Zaucha-Prazmo, A.; Wójcik, B.; Drabko, K.; Choma, M.; Kowalczyk, J.R. Cytomegalovirus (CMV) infections in children undergoing hematopoetic stem cell transplantation. Pediatr. Hematol. Oncol., 2005, 22 (4), 271-276.
53. Hebart, H.; Einsele, H. Clinical aspects of CMV infection after stem cell transplantation. Hum. Immunol., 2004, 65 (5), 432-436.
54. Boeckh, M.; Leisenring, W.; Riddell, S.R.; Bowden, R.A.; Huang, M.L.; Myerson, D.; Stevens-Ayers, T.; Flowers, M.E.; Cunningham, T.; Corey, L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood, 2003, 101 (2), 407-414.
55. Gluckman, E.; Traineau, R.; Devergie, A.; Esperou-Bourdeau, H.; Hirsch I. Prevention and treatment of CMV infection after allogeneic bone marrow transplant. Ann. Hematol., 1992, 64 (Suppl.), A158-A161.
56. Wingard, J.R.; Chen, D.Y.; Burns, W.H.; Fuller, D.J.; Braine, M.L.; Yeager, A.M.; Kaiser, H.; Burke, P.J.; Graham, M.L.; Santos, G.W. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood, 1988, 71 (5), 1432-1437.
57. Ljungman, P.; Biron, P.; Bosi, A.; Cahn, J.Y.; Goldstone, A.H.; Gorin, N.C.; Link, H.; Messina, C.; Michallet, M.; Richard, C.; Verdonck, L.; For the Infectious Disease Working Party of the European Group for Bone Marrow Transplantation. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Bone Marrow Transplant, 1994, 13 (2), 209-212.
58. Boeckh, M.; Gooley, T.A.; Reusser, P.; Buckner, C.D.; Bowden, R.A. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J. Infect. Dis., 1995, 172 (4), 939-943.
59. Hakki, M.; Riddell, S.R.; Storek, J.; Carter, R.A.; Stevens-Ayers, T.; Sudour, P.; White, K.; Corey, L.; Boeckh, M. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood, 2003, 102 (8), 3060-3067.
60. Walker, C.M.; van Burik, J.A.; De For, T.E.; Weisdorf, D.J. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol. Blood Marrow Transplant, 2007, 13 (9), 1106-1115.
61. Graber, C.; de Almeider, K.N.; Childs, R.; Barrett, A.J.; Gill, V.J.; Bennett, J.E. CMV reactivation in nonmyeloablative HSCT. Bone Marrow Transplant., 2001, 27 (7), 775.
62. Junghanss, C.; Boeckh, M.; Carter, R.A.; Sandmaier, B.M.; Maris, M.B.; Maloney, D.G.; Chauncey, T.; McSweeney, P.A.; Little, M.T.; Corey, L.; Storb, R. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood, 2002, 99 (6), 1978-1985.
63. Schetelig, J.; Oswald, O.; Steuer, N.; Radonic A.; Thulke, S.; Held, T.K.; Oertel, J.; Nitsche, A.; Siegert, W. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity of myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant., 2003, 32 (7), 695-701.
64. George, B.; Pati, N.; Gilroy, N.; Ratnamohan, M.; Huang, G.; Kerridge, I.; Hertzberg, M.; Gottlieb, D.; Bradstock, K. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl. Infect. Dis., 2010, 12 (4), 322-329.
65. Lin, T.S.; Zahrieh, D.; Weller, E.; Alyea, E.P.; Antin, J.H.; Soiffer, R.J. Risk factors for cytomegalovirus reactivation after CD6+ Tcell- depleted allogeneic bone marrow transplantation. Transplantation, 2002, 74 (1), 49-54.
66. Almyroudis, N.G.; Jakubowski, A.; Jaffe, D.; Sepkowitz, K.; Pamer, E.; O'Reilly, R.J.; Papanicolaou, G.A. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis., 2007, 9 (4), 286-294.
67. Zaia, J.A. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant., 2002, 29 (8), 633-638.
68. Asano-Mori, Y.; Kanda, Y.; Oshima, K.; Kako, S.; Shinohara, A.; Nakasone, H.; Sato, H.; Watanabe, T.; Hosoya, N.; Izutsu, K.; Asai, T.; Hangaishi, A.; Motokura, T.; Chiba, S.; Kurokawa, M. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation Int. J. Hematol., 2008, 87 (3), 310-318.
69. Yoon, H.S.; Lee, J. H.; Choi, E.S.; Seo, J.J.; Moon, H.N.; Kim, M.N.; Im, H.J. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors. Pediatr. Transplant., 2009, 13 (7), 898-905.
70. Marty, F.M.; Bryar, J.; Browne, S.K.; Schwarzberg, T.; Ho, V.T.; Bassett, I.V.; Koreth, J.; Alyea, E.P.; Soiffe, R.J.; Cutler, C.S.; Antin, J.H.; Baden, L.R. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood, 2007, 110 (2), 490-500.
71. Boeckh, M.; Nichols, W.G. Immunosuppressive effects of betaherpesviruses. Herpes, 2003, 10 (1), 12-16.
72. Torres, H.A.; Aguilera, E.; Safdar, A.; Rohatgi, N.; Raad, I.I.; Sepulveda, C.; Luna, M.; Kontoyiannis, D.P.; Chemaly, R.F. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin. Microbiol. Infect., 2008, 14 (12), 1160-1166.
73. Wang, F.Z.; Larsson, K.; Linde, A.; Ljungman, P. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients. Bone Marrow Transplant., 2002, 30 (8), 521-526.
74. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm. Rep., 2000, 49 (RR-10), 1-125, CE1-7.
75. Yahav, D.; Gafter-Gvili, A.; Muchtar, E.; Skalsky, K.; Kariv, G.; Yeshurun, M.; Leibovici, L.; Paul, M. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur. J. Cancer, 2009, 45 (18), 3131-3148.
76. Lim, Z.Y.; Cook, G.; Johnson, P.R.; Parker, A.; Zuckerman, M.; Marks, D.; Wiltshire, H.; Mufti, G.J.; Pagliuca, A. Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclocir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk. Res., 2009, 33 (2), 244-249.
77. Van der Heiden, P.L.; Kalpoe, J.S.; Barge, R.M.; Willemze, R.; Kroes, A.C.; Schippers, E.F. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant., 2006, 37 (7), 693-698.
78. Ayala, E.; Greene, J.; Sandin, R.; Perkins, J.; Field, T.; Tate, C.; Fields, K.K.; Goldstein, S. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant., 2006, 37 (9), 851-856.
79. Meijer, E.; Boland, G.J.; Verdonck, L.F. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin. Microbiol. Rev., 2003, 16 (4), 647-657.
80. Tuthill, M.; Chen, F.; Paston, S.; De La Peña, H.; Rusakiewicz, S.; Madrigal, A. The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation. Cancer Immunol. Immunother., 2009, 58 (9), 1481-1488.
81. Jancel, T; Penzak, S.R. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Semin. Hematol., 2009, 46 (3), 230-247.
82. Moretti, S.; Zikos, P.; Van Lint, M.T.; Tedone, E.; Occhini, D.; Gualandi, F.; Lamparelli, T.; Mordini, N.; Berisso, G.; Bregante, S.; Bruno, B.; Bacigalupo, A. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomized study. Bone Marrow Transplant., 1998, 22 (2), 175-180.
83. Reusser, P.; Einsele, H.; Lee J.; Volin, L.; Rovira, M.; Engelhard, D.; Finke, J.; Cordonnier, C.; Link, H.; Ljungman, P; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood, 2002, 99 (4), 1159-1164.
84. Raanani, P.; Gafter-Gvili, A.; Paul, M.; Ben-Bassat, I.; Leibovici, L.; Shpilberg, O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stemcell transplantation. Cochrane Database Syst. Rev., 2008, 8 (4), CD006501.
85. Schmidt-Hieber, M.; Schwarck, S.; Stroux, A.; Thiel, E.; Ganepola, S.; Uharek, L.; Blau, I.W. Prophylactic IVIG in patients with a high risk for CMV after allo-SCT. Bone Marrow Transplant., 2009, 44 (3), 185-192.
86. Micklethwaite, K.P.; Clancy, L.; Sandher, U.; Hansen, A.M.; Blyth, E.; Antonenas, V.; Sartor, M.M.; Bradstock, K.F.; Gottleib, D.J. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood, 2008, 112 (10), 3974-3981.
87. Reusser, P; Cordonnier, C.; Einselle, H.; Engelhard, D.; Link, D.; Locasciulli, A.; Ljungman, P. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant., 1996, 17 (5), 813-817.
88. Allice, T.; Busca, A.; Locatelli, F.; Falda, M.; Pittaluga, F.; Ghisetti, V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J. Antimicrob. Chemother., 2009, 63 (3), 600-608.
89. Wolf, D.G.; Yaniv, I.; Honigman, A.; Kassis, I.; Schonfeld, T.; Ashkenazi, S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J. Infect. Dis., 1998, 178 (2), 535-538.
90. Prix, L.; Hamprecht, K.; Holzhüter, B.; Handgretinger, R.; Klingebiel, T.; Jahn, G. Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J. Infect. Dis., 1999, 180 (2), 491-495
91. Razonable, R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm., 2005, 62 (8 Suppl. 1), S7-S13.
92. Springer, K.L.; Chou S.; Li, S.; Giller R.H.; Quinones, R.; Shira, J.E.; Weinberg, A. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus- infected hematopoietic cell transplant recipients. J. Clin. Microbiol., 2005, 43 (1), 208-213.
93. Seo, S.K.; Regan, A.; Cihlar, T.; Lin, D.C.; Boulad, F.; George, D.; Prasad, V.K.; Kiehn, T.E.; Polsky, B. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. Clin. Infect. Dis., 2001, 33 (9), e105-e108.
94. Cvetković, R.S.; Wellington, K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs, 2005, 65 (6), 859-878.
95. Mofenson, L.M.; Brady, M.T.; Danner, S.P.; Dominguez, K.L.; Hazra, R.; Handelsman, E.; Havens, P.; Nesheim, S.; Read, J.S.; Serchuck, L.; Van Dyke, R.; Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm. Rep., 2009, 58 (RR-11), 1-166
96. Rutstein, R.M.; Starr, S.E. In: Herpesvirus infections. Textbook of Pediatric HIV Care; Zeichner, S., Read, J., Eds.; Cambridge University Press: United Kingdom, 2005; pp. 604-619.
97. Chandwani, S.; Kaul, A.; Bebenroth, D.; Kim, M.; John, D.D.; Fidelia, A.; Hassel, A.; Borkowsky, W.; Krasinski, K. Cytomegalovirus infection in human immunodeficiency virus type 1-infected children. Pediatr. Infect. Dis. J., 1996, 15 (4), 310-314.
98. Kitchen, B.J.; Engler, H.D.; Gill, V.J.; Marshall, D.; Steinberg, S.M.; Pizzo, P.A.; Mueller, B.U. Cytomegalovirus infection in children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J., 1997, 16 (4), 358-363.
99. Madsen, M.; Nielsen, H. Cytomegalovirus esophagitis in a child with human immunodeficiency virus-1 infection presenting as fever of unknown origin and stunted growth. Eur. J. Pediatr., 2006, 165 (9), 665-666.
100. Nastouli, E.; Carrol, E.; Malone, M.; Riordan, A.; Lyall, H. Fatal histiocytic proliferative disorders in paediatric HIV infection with cytomegalovirus end-organ disease. Br. J. Haematol., 2009, 146 (5), 580-582.
101. Kovacs, A.; Schluchter, M.; Easley, K.; Demmler, G.; Shearer, W.; La Russa, P.; Pitt, J.; Cooper, E.; Goldfarb, J.; Hodes, D.; Kattan, M.; McIntosh, K. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N. Engl. J. Med., 1999, 341 (2), 77-84.
102. Darwich, L.; Cabrera, C.; Romeu, J.; Martinez-Picado, J.; Esté, J.A.; Tural, C.; Bellido, R.; Clotet, B.; Angulo, A.; Ruiz, L.; Bofill, M. The magnitude of interferon-gamma responses to human cytomegalovirus is predictive for HIV-1 disease progression. J. Acquir. Immune Defic. Syndr., 2008, 49 (5), 507-512.
103. Boppana, S.B.; Ross, S.A.; Novak, Z.; Shimamura, M.; Tolan, R.W., Jr.; Palmer, A.L.; Ahmed, A.; Michaels, M.G.; Sánchez, P.J.; Bernstein, D.I.; Britt, W.J.; Fowler, K.B.; National Institute on Deafness and Other Communication Disorders CMV and Hearing Multicenter Screening (CHIMES) Study. Evaluation of dried blood spot polymerase chain reaction as a method to screen newborns for congenital cytomegalovirus infection. JAMA. 2010, 303 (14), 1375-1382.
104. Benson, C.A.; Kaplan, J.E.; Masur, H.; Pau, A.; Holmes, K.K.; CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm. Rep., 2004, 53 (RR-15), 1-112.
105. Weinberg, A.; Wiznia, A.A.; Lafleur, B.J.; Shah, S.; Levin, M.J. Cytomegalovirus-specific cell-mediated immunity in HIV-infected children on HAART. AIDS Res. Hum. Retroviruses, 2006, 22 (3), 283-288.